Nuts and Bolts of Fecal Microbiota Transplantation

Clinical Gastroenterology and Hepatology

Volumn 17, Issue 2, 2019, Pages 345-352

  Krajicek, Edward ^a   Fischer, Monika ^a   Allegretti, Jessica R ^b   Kelly, Colleen R ^c  

^a INDIANA UNIVERSITY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

Clostridium difficile; fecal transplant; FMT; microbiome

Indexed keywords

CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLOSTRIDIUM DIFFICILE INFECTION; COUNSELING; DONOR SELECTION; FECAL MICROBIOTA TRANSPLANTATION; FOLLOW UP; HOSPITAL DISCHARGE; INFORMED CONSENT; NONHUMAN; PATIENT SAFETY; PATIENT SELECTION; PRACTICE GUIDELINE; REVIEW; TREATMENT INDICATION; ADVERSE EVENT; CLOSTRIDIUM INFECTION; CROSS INFECTION; HUMAN; PROCEDURES; SECONDARY PREVENTION; TREATMENT OUTCOME; UNITED STATES;

CLOSTRIDIUM INFECTIONS; CROSS INFECTION; FECAL MICROBIOTA TRANSPLANTATION; HUMANS; SECONDARY PREVENTION; TREATMENT OUTCOME; UNITED STATES;

EID: 85059172072     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2018.09.029     Document Type: Review

References (73)

1. Khanna, S., Microbiota replacement therapies: innovation in gastrointestinal care. Clin Pharmacol Ther 103 (2018), 102–111.
2. Lynch, S.V., Pedersen, O., The human intestinal microbiome in health and disease. N Engl J Med 375 (2016), 2369–2379.
3. Quraishi, M.N., Widlak, M., Bhala, N., et al. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther 46 (2017), 479–493.
4. Eiseman, B., Silen, W., Bascom, G.S., Kauvar, A.J., Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 44 (1958), 854–859.
5. Schwan, A., Sjölin, S., Trottestam, U., Aronsson, B., Relapsing Clostridium difficile enterocolitis cured by rectal infusion of homologous faeces. Lancet, 2, 1983, 845.
6. Khanna, S., Tosh, P.K., A clinician's primer on the role of the microbiome in human health and disease. Mayo Clin Proc 89 (2014), 107–114.
7. Khanna, S., Pardi, D.S., Clinical implications of antibiotic impact on gastrointestinal microbiota and Clostridium difficile infection. Expert Rev Gastroenterol Hepatol, 2016 Mar 16 [E-pub ahead of print].
8. Kassam, Z., Lee, C.H., Yuan, Y., Hunt, R.H., Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 108 (2013), 500–508.
9. Gupta, A., Khanna, S., Fecal microbiota transplantation. JAMA, 318, 2017, 102.
10. Sadowsky, M.J., Khoruts, A., Faecal microbiota transplantation is promising but not a panacea. Nat Microbiol, 1, 2016, 16015.
11. Weingarden, A.R., Chen, C., Bobr, A., et al. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am J Physiol Gastrointest Liver Physiol 306 (2014), G310–G319.
12. Cammarota, G., Ianiro, G., Gasbarrini, A., Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol 48 (2014), 693–702.
13. Kelly, C.R., Khoruts, A., Staley, C., et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial. Ann Intern Med 165 (2016), 609–616.
14. van Nood, E., Dijkgraaf, M.G., Keller, J.J., Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368 (2013), 407–415.
15. Youngster, I., Russell, G.H., Pindar, C., Ziv-Baran, T., Sauk, J., Hohmann, E.L., Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 312 (2014), 1772–1778.
16. Arbel, L.T., Hsu, E., McNally, K., Cost-effectiveness of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection: a literature review. Cureus, 9, 2017, e1599.
17. Merlo, G., Graves, N., Brain, D., Connelly, L.B., Economic evaluation of fecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection in Australia. J Gastroenterol Hepatol 31 (2016), 1927–1932.
18. Drekonja, D., Reich, J., Gezahegn, S., et al. Fecal microbiota transplantation for Clostridium difficile infection: a systematic review. Ann Intern Med 162 (2015), 630–638.
19. Bakken, J.S., Polgreen, P.M., Beekmann, S.E., Riedo, F.X., Streit, J.A., Treatment approaches including fecal microbiota transplantation for recurrent Clostridium difficile infection (RCDI) among infectious disease physicians. Anaerobe 24 (2013), 20–24.
20. Allegretti, J.R., Kassam, Z., Osman, M., Budree, S., Fischer, M., Kelly, C.R., The 5D framework: a clinical primer for fecal microbiota transplantation to treat Clostridium difficile infection. Gastrointest Endosc 87 (2018), 18–29.
21. Kelly, C.R., Kahn, S., Kashyap, P., et al. Update on fecal microbiotatransplantation 2015: indications, methodologies, mechanisms, and outlook. Gastroenterology 149 (2015), 223–237.
22. Bakken, J.S., Borody, T., Brandt, L.J., et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 9 (2011), 1044–1049.
23. Hartmann, K.E., Jerome, R.N., Lindegren, M.L., et al. Primary care management of abnormal uterine bleeding. 2013, AHRQ, Rockville, MD.
24. Cammarota, G., Ianiro, G., Tilg, H., et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut 66 (2017), 569–580.
25. McDonald, L.C., Gerding, D.N., Johnson, S., et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 66 (2018), 987–994.
26. Fischer, M., Sipe, B.W., Rogers, N.A., et al. Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate. Aliment Pharmacol Ther 42 (2015), 470–476.
27. Fischer, M., Sipe, B., Cheng, Y.W., et al. Fecal microbiota transplant in severe and severe-complicated Clostridium difficile: a promising treatment approach. Gut Microbes 8 (2017), 289–302.
28. Aroniadis, O.C., Brandt, L.J., Greenberg, A., et al. Long-term follow-up study of fecal microbiota transplantation for severe and/or complicated Clostridium difficile infection: a multicenter experience. J Clin Gastroenterol 50 (2016), 398–402.
29. Hocquart, M., Lagier, J.C., Cassir, N., et al. Early fecal microbiota transplantation improves survival in severe Clostridium difficile infections. Clin Infect Dis 66 (2018), 645–650.
30. Cammarota, G., et al. Decrease in surgery for Clostridium difficile infection after starting a program to transplant fecal microbiota. Ann Intern Med 163 (2015), 487–488.
31. Crobach, M.J., Ianiro, G., Magalini, S., Gasbarrini, A., Gui, D., European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect 22:Suppl 4 (2016), S63–S81.
32. Jackson, M., Olefson, S., Machan, J.T., Kelly, C.R., A high rate of alternative diagnoses in patients referred for presumed Clostridium difficile infection. J Clin Gastroenterol 50 (2016), 742–746.
33. Khoruts, A., Rank, K.M., Newman, K.M., et al. Inflammatory bowel disease affects the outcome of fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol 14 (2016), 1433–1438.
34. Kelly, C.R., Ihunnah, C., Fischer, M., et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 109 (2014), 1065–1071.
35. Saeedi, B.J., Morison, D.G., Kraft, C.S., Dhere, T., Fecal microbiota transplant for Clostridium difficile infection in a pregnant patient. Obstet Gynecol 129 (2017), 507–509.
36. Allegretti, J., Eysenbach, L.M., El-Nachef, N., Fischer, M., Kelly, C., Kassam, Z., The current landscape and lessons from fecal microbiota transplantation for inflammatory bowel disease: past, present, and future. Inflamm Bowel Dis 23 (2017), 1710–1717.
37. Edelstein, C., Daw, J.R., Kassam, Z., Seeking safe stool: Canada needs a universal donor model. CMAJ 188 (2016), E431–E432.
38. Smith, M., Kassam, Z., Edelstein, C., Burgess, J., Alm, E., OpenBiome remains open to serve the medical community. Nat Biotechnol, 32, 2014, 867.
39. Kelly, C.R., Kunde, S.S., Khoruts, A., Guidance on preparing an investigational new drug application for fecal microbiota transplantation studies. Clin Gastroenterol Hepatol 12 (2014), 283–288.
40. Lee, C.H., Steiner, T., Petrof, E.O., et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA 315 (2016), 142–149.
41. Kao, D., Roach, B., Silva, M., et al. Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: a randomized clinical trial. JAMA 318 (2017), 1985–1993.
42. Costello, S.P., Tucker, E.C., La Brooy, J., Schoeman, M.N., Andrews, J.M., Establishing a fecal microbiota transplant service for the treatment of Clostridium difficile infection. Clin Infect Dis 62 (2016), 908–914.
43. Budree, S., Rao, S., Allegretti, J.R., et al. The association of donor stool consistency by Bristol stool scale on microbial profile and clinical outcomes of fecal microbiota transplantation in Clostridium difficile infection. Gastroenterology, 152, 2017, S630.
44. Budree, S., Wong, W.F., Tu, E., et al. Do specific bacteria drive clinical cure in fecal microbiota transplantation for Clostridium difficile infection?: clinical, microbial and metabolomic characterization of universal FMT donors. Gastroenterology, 152, 2017, S349.
45. Budree, S., Tu, E., Leith, T., et al. The association of stool donor diet on microbial profile and clinical outcomes of fecal microbiota transplantation in Clostridium difficile infection. Gastroenterology 152 (2017), S630–S631.
46. Brandt, L.J., Aroniadis, O.C., Mellow, M., et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 107 (2012), 1079–1087.
47. Baxter, M., Colville, A., Adverse events in faecal microbiota transplant: a review of the literature. J Hosp Infect 92 (2016), 117–127.
48. Fischer, M., Kao, D., Kelly, C., et al. Fecal microbiota transplantation is safe and efficacious for recurrent or refractory Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis 22 (2016), 2402–2409.
49. Wang, S., Xu, M., Wang, W., et al. Systematic review: adverse events of fecal microbiota transplantation. PLoS One, 11, 2016, e0161174.
50. Qazi, T., Amaratunga, T., Barnes, E.L., Fischer, M., Kassam, Z., Allegretti, J.R., The risk of inflammatory bowel disease flares after fecal microbiota transplantation: systematic review and meta-analysis. Gut Microbes 8 (2017), 574–588.
51. Newman, K.M., Rank, K.M., Vaughn, B.P., Khoruts, A., Treatment of recurrent Clostridium difficile infection using fecal microbiota transplantation in patients with inflammatory bowel disease. Gut Microbes 8 (2017), 303–309.
52. Rossen, N.G., Fuentes, S., van der Spek, M.J., et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 149 (2015), 110–118 e4.
53. Paramsothy, S., Kamm, eMA., Kaakoush, N.O., et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet 389 (2017), 1218–1228.
54. Moayyedi, P., Kamm, M.A., Kaakoush, N.O., et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 149 (2015), 102–109.e6.
55. Brandt, L.J., Aroniadis, O.C., An overview of fecal microbiota transplantation: techniques, indications, and outcomes. Gastrointest Endosc 78 (2013), 240–249.
56. Zipursky, J.S., Sidorsky, T.I., Freedman, C.A., Sidorsky, M.N., Kirkland, K.B., Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection. Clin Infect Dis 55 (2012), 1652–1658.
57. Baxter, M., Ahmad, T., Colville, A., Sheridan, R., Fatal aspiration pneumonia as a complication of fecal microbiota transplant. Clin Infect Dis 61 (2015), 136–137.
58. van Beurden, Y.H., van Gils, T., van Gils, N.A., Kassam, Z., Mulder, C.J., Aparicio-Pagés, N., Serendipity in refractory celiac disease: full recovery of duodenal villi and clinical symptoms after fecal microbiota transfer. J Gastrointestin Liver Dis 25 (2016), 385–388.
59. Hirsch, B.E., Saraiya, N., Poeth, K., Schwartz, R.M., Epstein, M.E., Honig, G., Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection. BMC Infect Dis, 15, 2015, 191.
60. Allegretti, J.R., Storm, M., Smith, M., et al. Su1739 strain-level analysis of microbial engraftment associated with resolution of recurrent Clostridium difficile following fecal microbiota transplantation. Gastroenterology 150 (2016), S540–S541.
61. Fischer, M., Phelps, E., Kao, D., Xu, H., Kelly, C., Response to bodiwala and skole. Am J Gastroenterol 112 (2017), 391–392.
62. Ianiro, G., Valerio, L., Masucci, L., et al. Predictors of failure after single faecal microbiota transplantation in patients with recurrent Clostridium difficile infection: results from a 3-year, single-centre cohort study. Clin Microbiol Infect, 23, 2017, 337.e3.
63. De Filippis, F., Pellegrini, N., Vannini, L., et al. High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome. Gut 65 (2016), 1812–1821.
64. Allegretti, J.R., Kao, D., Sitko, J., Fischer, M., Kassam, Z., Early antibiotic use after fecal microbiota transplantation increases risk of treatment failure. Clin Infect Dis 66 (2018), 134–135.
65. Fischer, M., Phelps, E., Bolla, R., Storm, M., Allegretti, J.R., 93 Long-term risk of Clostridium difficile infection recurrence with or without antibiotic exposure following successful fecal microbiota transplant. Gastroenterology, 150, 2016, S23.
66. Shen, N.T., Maw, A., Tmanova, L.L., et al. Timely use of probiotics in hospitalized adults prevents Clostridium difficile infection: a systematic review with meta-regression analysis. Gastroenterology 152 (2017), 1889–1900.e9.
67. Van Hise, N.W., Bryant, A.M., Hennessey, E.K., Crannage, A.J., Khoury, J.A., Manian, F.A., Efficacy of oral vancomycin in preventing recurrent Clostridium difficile infection in patients treated with systemic antimicrobial agents. Clin Infect Dis 63 (2016), 651–653.
68. Allegretti, J.R., Allegretti, A.S., Phelps, E., Xu, H., Fischer, M., Kassam, Z., Classifying fecal microbiota transplantation failure: an observational study examining timing and characteristics of fecal microbiota transplantation failures. Clin Gastroenterol Hepatol 16 (2018), 1832–1833.
69. Wilcox, M.H., Kelly, C.P., Rahav, G., et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med 376 (2017), 305–317.
70. Johnsen, P.H., Hilpüsch, F., Cavanagh, J.P., et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol Hepatol 3 (2018), 17–24.
71. Bajaj, J.S., Kassam, Z., Fagan, A., et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial. Hepatology 66 (2017), 1727–1738.
72. Millan, B., Laffin, M., Madsen, K., Fecal microbiota transplantation: beyond Clostridium difficile. Curr Infect Dis Rep, 19, 2017, 31.
73. Kootte, R.S., Levin, E., Salojärvi, J., et al. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. Cell Metab 26 (2017), 611–619.e6.